BCRX (BioCryst Pharmaceuticals) FFO


BCRX BioCryst Pharmaceuticals Inc BCRX
62 GF Score
Price $10.00
GF Value $12.77
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

BCRX
62GF Score
BioCryst Pharmaceuticals Inc BCRX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of $10.00 is trading 21.7% below its estimated GF Value™ of $12.77. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BCRX:

  • FFO:
  • GF Value™: $12.77 vs. price of $10.00 (21.7% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:MexicoBO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
62GF Score

Get the complete analysis for BCRX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.00
Price
$12.77
GF Value